Literature DB >> 10378822

Concomitant use of intraaortic balloon counterpulsation and streptokinase in acute anterior myocardial infarction.

S D Kumbasar1, E Semiz, O Sancaktar, S Yalçinkaya, C Ermiş, N Değer.   

Abstract

Using a prospective, nonrandomized design, the authors sought to determine whether concomitant use of intraaortic balloon counterpulsation (IABP) and streptokinase in acute anterior myocardial infarction (MI) would improve the in-hospital mortality rate and angiographic findings. The study included 45 patients with an acute anterior MI. All patients received intravenous streptokinase. Among these, 25 patients had concomitant IABP while the remaining 20 patients had streptokinase alone. All patients underwent cardiac catheterization. Patients treated with concomitant IABP had a significantly higher frequency of thrombolysis in myocardial infarction (TIMI) grade 3 flow (n: 11; 44% vs n: 1; 5%, p<0.05), and there was a trend toward a lower in-hospital mortality rate in the IABP group (n: 0; 0% vs n: 3; 15%, p=0.08). The angiographic presence of thrombus image and grade > or =2 coronary collateral circulation to the infarct-related coronary artery for the IABP and non-IABP groups did not differ significantly. The preliminary results of this study suggest that concomitant use of IABP and streptokinase in acute anterior MI increases the incidence of TIMI grade 3 flow and may have decreased the in-hospital mortality rate without unacceptable rates of vascular or hemorrhagic complications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10378822     DOI: 10.1177/000331979905000604

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  1 in total

1.  The outcomes of intra-aortic balloon pump usage in patients with acute myocardial infarction: a comprehensive meta-analysis of 33 clinical trials and 18,889 patients.

Authors:  Zhong-Guo Fan; Xiao-Fei Gao; Li-Wen Chen; Xiao-Bo Li; Ming-Xue Shao; Qian Ji; Hao Zhu; Yi-Zhi Ren; Shao-Liang Chen; Nai-Liang Tian
Journal:  Patient Prefer Adherence       Date:  2016-03-16       Impact factor: 2.711

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.